Leading Pharmacy Law Plaintiffs Firm Gilman Law LLP Alerts Consumers to Recent Supreme Court Ruling Severely Limiting Their Rights in Defective Drug and Pharmaceutical Cases

Boston, MA (PRWEB) March 20, 2013

Leading pharmacy law and defective drugs plaintiffs law firm Gilman Law LLP is representing individuals in product liability claims involving defective drug side effects and dangerous medical devices, and is alerting consumers to recent and impending Supreme Court decisions that may greatly limit their rights to pursue compensation for any injuries caused by generic drug side effects. In 2011, the Supreme Court ruled in Pliva v. Mensing that federal law pre-empts state failure-to-warn laws that impose a duty or liability on generic drug makers to warn the public of dangerous side effects. The effect of the decision has prevented victims of generic drug injuries from pursuing failure-to-warn claims against generic drug manufacturers regardless of the merits of such a claim. [Pliva v. Mensing, 131 S. Ct. 2567 (2011)]

The defective drug and products liability law firm of Gilman Law LLP can provide a free legal consultation with no cost or obligation to individuals that have been injured by a defective drug or defective medical device. Contact our defective drug lawyers TOLL FREE at 888-252-0048 or submit a free legal consultation form online.

The Supreme Courts Upcoming Decision May Limit Consumer Rights

On March 18th, the Supreme Court heard oral arguments in another generic drug case, Bartlett v. Mutual Pharm. Co., Inc. According to Ken Gilman of Gilman Law, LLP, “Depending on the Courts decision in Bartlett, consumers could lose additional rights to recover for the victims of generic drug injuries.” Unfortunately, most consumers are not aware of the Mensing or Bartlett decisions, or that they may not be able to recover for injuries against generic drug manufacturers according to Gilman Law. (Mutual Pharmaceutical Co. v. Bartlett, 12-142.)

In response to this news, Gilman Law continues to offer free case evaluations for the following drugs and medical devices:

Leave a Reply